Investor
News & Events
Financial Reports
Stock Information
Corporate Governance
Contacts & Alerts
WASHINGTON, Oct. 18, 2018 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2018. For the quarter ended September 28, 2018, net earnings were $663.7 million, or $0.93 per diluted share which represents a 15.0% year-over-year increase.
Non-GAAP adjusted diluted net earnings per share for the third quarter were $1.10. This represents a 10.0% increase over the comparable 2017 period. For the third quarter 2018, revenues increased 7.0% year-over-year to $4.9 billion, with non-GAAP core revenue growth of 6.5%.
For the fourth quarter 2018, the Company anticipates that diluted net earnings per share will be in the range of $1.04 to $1.07 and non-GAAP adjusted diluted net earnings per share will be in the range of $1.25 to $1.28.
For the full year 2018, the Company is increasing its diluted net earnings per share guidance to a range of $3.72 to $3.75 versus previous guidance of $3.64 to $3.71. The Company is increasing its 2018 non-GAAP adjusted diluted net earnings per share guidance to a range of $4.49 to $4.52 versus previous guidance of $4.43 to $4.50.
Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "We are very pleased with our performance in the third quarter, as the team maintained strong momentum and delivered outstanding results. We achieved 6.5% core revenue growth, solid operating margin expansion and double-digit adjusted earnings per share growth. Four of our five platforms delivered mid-single digit or better core revenue growth, and we believe our investments in innovation and commercial execution are driving market share gains in many of our businesses."
Joyce continued, "Our recent performance is a testament to the team's execution and drive for continuous improvement. We believe the strength and differentiation of our portfolio - combined with the power of the Danaher Business System - provides us with the foundation to deliver sustainable, long-term shareholder value."
Danaher will discuss its results during its quarterly investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
The conference call can be accessed by dialing 877-260-1479 within the U.S. or by dialing +1 334-323-0522 outside the U.S. a few minutes before the 8:00 a.m. ET start and telling the operator that you are dialing in for Danaher's investor conference call (access code 2512928). A replay of the conference call will be available shortly after the conclusion of the call and until October 25, 2018. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations." In addition, presentation materials relating to Danaher's results have been posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings."
All results in this release reflect only continuing operations unless otherwise noted.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in some of the most demanding and attractive industries, including health care, environmental and industrial. With more than 20 operating companies, Danaher's globally diverse team of approximately 67,000 associates is united by a common culture and operating system, the Danaher Business System. For more information, please visit www.danaher.com.
NON-GAAP MEASURES
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial performance for the fourth quarter and full year 2018, the Company's increasing market share, the Company's opportunities and positioning for 2018 and beyond and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, Danaher's ability to complete the previously-announced spin-off of its Dental business on the currently contemplated timeline and achieve the intended benefits, deterioration of or instability in the economy, the markets we serve and the financial markets, developments and uncertainties in U.S. policy stemming from the current administration, such as changes in U.S. trade and tariff policies and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures (including tax-related and other contingent liabilities relating to past and future split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom's decision to leave the EU), disruptions relating to man-made and natural disasters, and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2017 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2018. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
DANAHER CORPORATION AND SUBSIDIARIES | |||||||||||||||
CONSOLIDATED STATEMENTS OF EARNINGS (unaudited) | |||||||||||||||
($ and shares in millions, except per share amounts) | |||||||||||||||
Three-Month Period Ended | Nine-Month Period Ended | ||||||||||||||
September 28, | September 29, | September 28, | September 29, | ||||||||||||
Sales | $ | 4,853.1 | $ | 4,528.2 | $ | 14,529.5 | $ | 13,244.0 | |||||||
Cost of sales | (2,162.6) | (1,991.4) | (6,378.3) | (5,890.6) | |||||||||||
Gross profit | 2,690.5 | 2,536.8 | 8,151.2 | 7,353.4 | |||||||||||
Operating costs: | |||||||||||||||
Selling, general and administrative expenses | (1,558.6) | (1,498.4) | (4,798.4) | (4,470.6) | |||||||||||
Research and development expenses | (301.2) | (279.2) | (911.6) | (829.9) | |||||||||||
Operating profit | 830.7 | 759.2 | 2,441.2 | 2,052.9 | |||||||||||
Nonoperating income (expense): | |||||||||||||||
Other income, net | 9.1 | 8.3 | 25.2 | 22.2 | |||||||||||
Interest expense | (41.3) | (39.9) | (123.6) | (120.9) | |||||||||||
Interest income | 2.8 | 2.2 | 6.7 | 5.6 | |||||||||||
Earnings from continuing operations before income taxes | 801.3 | 729.8 | 2,349.5 | 1,959.8 | |||||||||||
Income taxes | (137.6) | (157.7) | (445.4) | (346.6) | |||||||||||
Net earnings from continuing operations | 663.7 | 572.1 | 1,904.1 | 1,613.2 | |||||||||||
Earnings from discontinued operations, net of income taxes | — | — | — | 22.3 | |||||||||||
Net earnings | $ | 663.7 | $ | 572.1 | $ | 1,904.1 | $ | 1,635.5 | |||||||
Net earnings per share from continuing operations: | |||||||||||||||
Basic | $ | 0.95 | $ | 0.82 | $ | 2.72 | $ | 2.32 | |||||||
Diluted | $ | 0.93 | $ | 0.81 | $ | 2.68 | $ | 2.29 | |||||||
Net earnings per share from discontinued operations: | |||||||||||||||
Basic | $ | — | $ | — | $ | — | $ | 0.03 | |||||||
Diluted | $ | — | $ | — | $ | — | $ | 0.03 | |||||||
Net earnings per share: | |||||||||||||||
Basic | $ | 0.95 | $ | 0.82 | $ | 2.72 | $ | 2.35 | |||||||
Diluted | $ | 0.93 | $ | 0.81 | $ | 2.68 | $ | 2.32 | |||||||
Average common stock and common equivalent shares outstanding: | |||||||||||||||
Basic | 701.4 | 696.2 | 700.1 | 695.3 | |||||||||||
Diluted | 710.6 | 705.6 | 709.9 | 705.5 | |||||||||||
This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com). |
DANAHER CORPORATION | |||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | |||||||||||||||
Adjusted Diluted Net Earnings Per Share from Continuing Operations | |||||||||||||||
Three-Month Period Ended | Nine-Month Period Ended | ||||||||||||||
September 28, 2018 | September 29, 2017 | September 28, 2018 | September 29, 2017 | ||||||||||||
Diluted Net Earnings Per Share from Continuing Operations (GAAP) | $ | 0.93 | $ | 0.81 | $ | 2.68 | $ | 2.29 | |||||||
Pretax amortization of acquisition-related intangible assets A | 0.25 | 0.24 | 0.75 | 0.70 | |||||||||||
Pretax acquisition-related transaction costs deemed significant and fair value adjustments to inventory, in each case related to the acquisition of IDT and incurred in the second quarter of 2018 B | — | — | 0.02 | — | |||||||||||
Pretax gain on resolution of acquisition-related matters recognized in the second quarter of 2018 C | — | — | (0.01) | — | |||||||||||
Pretax restructuring, impairment and other related charges recorded in the second quarter of 2017 D | — | — | — | 0.11 | |||||||||||
Tax effect of all adjustments reflected above E | (0.05) | (0.05) | (0.16) | (0.18) | |||||||||||
Discrete tax adjustments and other tax-related adjustments F | (0.03) | — | (0.04) | (0.08) | |||||||||||
Adjusted Diluted Net Earnings Per Share from Continuing Operations (Non-GAAP) | $ | 1.10 | $ | 1.00 | $ | 3.24 | $ | 2.84 |
Forecasted Adjusted Diluted Net Earnings Per Share from Continuing Operations 1 | |||||||||||||||
Three-Month Period Ending December 31, 2018 | Year Ending December 31, 2018 | ||||||||||||||
Low End | High End | Low End | High End | ||||||||||||
Forecasted Diluted Net Earnings Per Share from Continuing Operations (GAAP) | $ | 1.04 | $ | 1.07 | $ | 3.72 | $ | 3.75 | |||||||
Anticipated pretax amortization of acquisition-related intangible assets A | 0.25 | 0.25 | 1.00 | 1.00 | |||||||||||
Pretax acquisition-related transaction costs deemed significant and fair value adjustments to inventory, in each case related to the acquisition of IDT and incurred in the second quarter of 2018 B | — | — | 0.02 | 0.02 | |||||||||||
Pretax gain on resolution of acquisition-related matters recognized in the second quarter of 2018 C | — | — | (0.01) | (0.01) | |||||||||||
Pretax costs incurred in the three-month period ending December 31, 2018 related to preparation for the 2019 separation of the Dental segment ("Dental Separation") primarily related to professional fees for legal, tax, finance and information technology services G | 0.01 | 0.01 | 0.01 | 0.01 | |||||||||||
Tax effect of all adjustments reflected above E | (0.05) | (0.05) | (0.21) | (0.21) | |||||||||||
Discrete tax adjustments and other tax-related adjustments F | — | — | (0.04) | (0.04) | |||||||||||
Forecasted Adjusted Diluted Net Earnings Per Share from Continuing Operations (Non-GAAP) | $ | 1.25 | $ | 1.28 | $ | 4.49 | $ | 4.52 | |||||||
1 | These forward-looking estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as certain future gains or losses on the sale of investments, acquisition or divestiture-related gains or charges and discrete tax items. |
DANAHER CORPORATION | |||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | |||||
(continued) | |||||
Core Revenue | |||||
% Change Three- Month Period Ended September 28, 2018 vs. Comparable 2017 Period | % Change Nine- Month Period Ended September, 2018 vs. Period | ||||
Total Revenue Growth from Continuing Operations (GAAP) | 7.0 | % | 9.5 | % | |
Less the impact of: | |||||
Acquisitions | (2.0) | % | (1.5) | % | |
Currency exchange rates | 1.5 | % | (2.0) | % | |
Core Revenue Growth from Continuing Operations (Non-GAAP) 2 | 6.5 | % | 6.0 | % | |
2 | We use the term "core revenue" to refer to GAAP revenue from continuing operations excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition less the amount of sales attributable to divested businesses or product lines not considered discontinued operations ("acquisition sales") and (2) the impact of currency translation. The portion of GAAP revenue from continuing operations attributable to currency translation is calculated as the difference between (a) the period-to-period change in revenue (excluding acquisition sales) and (b) the period-to-period change in revenue (excluding acquisition sales) after applying current period foreign exchange rates to the prior year period. We use the term "core revenue growth" to refer to the measure of comparing current period core revenue with the corresponding period of the prior year. |
Free Cash Flow from Continuing Operations | |||||||
Nine-Month Period Ended | |||||||
September 28, 2018 | September 29, 2017 | ||||||
($ in millions): | |||||||
Operating Cash Flows from Continuing Operations (GAAP) | $ | 2,784.4 | $ | 2,643.1 | |||
Less: payments for additions to property, plant & equipment (capital expenditures) from continuing operations (GAAP) | (441.3) | (445.8) | |||||
Plus: proceeds from sales of property, plant & equipment (capital disposals) from continuing operations (GAAP) | 1.6 | 32.3 | |||||
Free Cash Flow from Continuing Operations (Non-GAAP) | $ | 2,344.7 | $ | 2,229.6 | |||
DANAHER CORPORATION | |||||||||||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | |||||||||||||||||||||||
(continued) | |||||||||||||||||||||||
A Amortization of acquisition-related intangible assets in the following historical and forecasted periods ($ in millions) (only the pretax | |||||||||||||||||||||||
Forecasted | |||||||||||||||||||||||
Three-Month Period Ended | Nine-Month Period Ended | Three-Month Period Ending | Year Ending | ||||||||||||||||||||
September 28, 2018 | September 29, 2017 | September 28, 2018 | September 29, 2017 | December 31, 2018 | December 31, 2018 | ||||||||||||||||||
Pretax | $ | 174.1 | $ | 166.4 | $ | 527.5 | $ | 492.9 | $ | 177.1 | $ | 704.6 | |||||||||||
After-tax | 139.1 | 131.5 | 420.4 | 391.0 | 141.7 | 562.1 | |||||||||||||||||
B | Acquisition-related transaction costs deemed significant ($15 million pretax as presented in this line item, $13 million after-tax), and fair value adjustments to inventory ($1 million pretax as presented in this line item, $0.8 million after-tax), in each case related to the acquisition of IDT and incurred in the second quarter of 2018. The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period. |
C | Net gains on resolution of acquisition-related matters in the Life Sciences segment ($9 million pretax as presented in this line item, $7 million after-tax) for the second quarter of 2018. |
D | During the second quarter of 2017, the Company recorded $76 million of pretax restructuring, impairment and other related charges ($51 million after-tax) primarily related to the Company's strategic decision to discontinue certain product development efforts in its Diagnostics segment. As a result, the Company incurred noncash charges for the impairment of certain technology-related intangibles as well as related inventory and plant, property, and equipment with no further use totaling $49 million. In addition, the Company incurred cash restructuring costs primarily related to employee severance and related charges totaling $27 million. This is addressed in more detail in the "Statement Regarding Non-GAAP Measures." |
E | This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnote above indicates the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. |
F | Represents discrete income tax gains, primarily related to the release of valuation allowances associated with certain foreign operating losses ($23 million and $32 million, respectively, in the three and nine-month periods ended September 28, 2018) and (1) $35 million in the nine-month period ended September 29, 2017 and (2) equity compensation-related excess tax benefits ($16 million in the nine-month period ended September 29, 2017). On January 1, 2017, Danaher adopted the updated accounting guidance required by ASU 2016-09, Compensation—Stock Compensation, which requires income statement recognition of all excess tax benefits and deficiencies related to equity compensation. We exclude from Adjusted Diluted Net EPS any excess tax benefits that exceed the levels we believe are representative of historical experience. In the first quarter of 2017, we anticipated $10 million of equity compensation-related excess tax benefits and realized $26 million of excess tax benefits, and therefore, we have excluded $16 million of these benefits in the calculation of Adjusted Diluted Net Earnings per Share. In the other periods presented, realized equity compensation-related excess tax benefits approximated the anticipated benefit and no adjustment was required. |
G | Pretax costs incurred in the three-month period ending December 31, 2018 ($10 million pretax as reported in this line item, $8 million after-tax) related to preparation for the 2019 separation of the Dental segment ("Dental Separation") primarily related to professional fees for legal, tax, finance and information technology services. |
Statement Regarding Non-GAAP Measures
Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors to:
Management uses these non-GAAP measures to measure the Company's operating and financial performance, and uses non-GAAP measures similar to Adjusted Diluted Net EPS and the FCF Measure in the Company's executive compensation program.
The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
SOURCE Danaher Corporation